Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Sanofi ( (SNY) ).
In July 2025, Sanofi announced two significant developments in its multiple myeloma treatment portfolio. On July 25, 2025, the European Commission approved Sarclisa in combination with VRd for the treatment of transplant-eligible newly diagnosed multiple myeloma patients, based on positive results from the GMMG-HD7 phase 3 study. This approval marks Sarclisa’s availability in the EU across all lines of therapy for multiple myeloma. Additionally, on July 30, 2025, Sanofi’s SAR446523, a GPRC5D monoclonal antibody, received orphan drug designation in the US for multiple myeloma, highlighting the company’s commitment to addressing unmet needs in cancer care.
The most recent analyst rating on (SNY) stock is a Hold with a $67.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall score is bolstered by strong earnings call performance and stable financial health, with positive strategic initiatives. Some caution is warranted due to cash flow weaknesses and valuation considerations.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is a research and development-driven, AI-powered biopharmaceutical company focused on improving lives through innovative medicines and vaccines. The company leverages its deep understanding of the immune system to develop treatments that address urgent healthcare challenges globally. Sanofi is publicly traded on EURONEXT and NASDAQ.
Average Trading Volume: 2,107,118
Technical Sentiment Signal: Buy
Current Market Cap: $119.9B
See more insights into SNY stock on TipRanks’ Stock Analysis page.